The SpyGlass Pharma™ Drug Delivery Platform combines safe, lasting treatment with the world's most common, routine ophthalmic surgery.
Spyglass Platform Pipeline
SpyGlass Pharma™ Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform
SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass platform is designed to be implanted at the time of routine cataract surgery and deliver multiple years of bimatoprost, to lower intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. (View full press release)